Evidence map›Paper›PMID 26985148›Full record

ArticleCurrent oncology (Toronto, Ont.)2016

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

C Popadiuk, C L Gauvreau, M Bhavsar, C Nadeau, K Asakawa, W M Flanagan, M C Wolfson, A J Coldman, S Memon, N Fitzgerald and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Exploring the role of the oncology nurse in cervical cancer screening programs during times of transition.Canadian oncology nursing journal = Revue canadienne de nursing oncologique · 2025
    Article
  3. Article
  4. The OncoSim-Breast Cancer Microsimulation Model.Current oncology (Toronto, Ont.) · 2022
    Article
  5. Estimates of future cancer mortality attributable to modifiable risk factors in Canada.Canadian journal of public health = Revue canadienne de sante publique · 2021
    Article
  6. Starting cervical cancer screening at 25 years of age: the time has come.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

C PopadiukDepartment of Women's Health, Memorial University, St. John's, NL;
C L GauvreauCanadian Partnership Against Cancer, Toronto, ON;
M BhavsarCanadian Partnership Against Cancer, Toronto, ON;
C NadeauStatistics Canada, Ottawa, ON;
K AsakawaStatistics Canada, Ottawa, ON;
W M FlanaganStatistics Canada, Ottawa, ON;
M C WolfsonUniversity of Ottawa, Ottawa, ON;
A J ColdmanCanadian Partnership Against Cancer, Toronto, ON;
S MemonCanadian Partnership Against Cancer, Toronto, ON;
N FitzgeraldCanadian Partnership Against Cancer, Toronto, ON;
J LacombeCanadian Partnership Against Cancer, Toronto, ON;
A B MillerDalla Lana School of Public Health, Toronto, ON.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Canada, discussion about changing from cytology to human papillomavirus (hpv) dna testing for primary screening in cervical cancer is ongoing. However, the Canadian Task Force on Preventive Health Care has not yet made a recommendation, concluding that the evidence is insufficient.

methodsWe used the cervical cancer and hpv transmission models of the Cancer Risk Management Model to study the health and economic outcomes of primary cytology compared with hpv dna testing in 14 screening scenarios with varying screening modalities and intervals. Projected cervical cancer cases, deaths, colposcopies, screens, costs, and incremental cost-effectiveness were evaluated. We performed sensitivity analyses for hpv dna test costs.

resultsCompared with triennial cytology from age 25, 5-yearly hpv dna screening alone from age 30 resulted in equivalent incident cases and deaths, but 55% (82,000) fewer colposcopies and 43% (1,195,000) fewer screens. At hpv dna screening intervals of 3 years, whether alone or in an age-based sequence with cytology, screening costs are greater, but at intervals of more than 5 years, they are lower. Scenarios on the cost-effectiveness frontier were hpv dna testing alone every 10, 7.5, 5, or 3 years, and triennial cytology starting at age 21 or 25 when combined with hpv dna testing every 3 years.

conclusionsChanging from cytology to hpv dna testing as the primary screening test for cervical cancer would be an acceptable strategy in Canada with respect to incidence, mortality, screening and diagnostic test volumes.

Indexed as

Canadacervical cancercytologyhpvdnaHuman papillomavirusmodellingscreening

Identifiers

PMID26985148
PMCPMC4780581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.